The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic ...

Obstructive sleep apnea severity measured via apnea-hypopnea index decreased among patients receiving AD109, an oral ...

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...

After a decade of development, a Kansas City-based pharmaceutical company is on the brink of submitting its ADHD medication ...

Aurinia Pharmaceuticals Inc. achieved record Lupkynis sales of $66.6M in Q2 while managing cash flow. Click for insights on ...

US FDA clears Hemispherian’s IND application for first-in-class glioblastoma therapeutic, GLIX1: Oslo, Norway Wednesday, August 6, 2025, 15:00 Hrs [IST] Hemispherian AS, a pione ...

Lantheus Holdings (NASDAQ:LNTH) announced on Wednesday that the U.S. Food and Drug Administration (FDA) accepted its ...

The US Food and Drug Administration (FDA) has approved Anbogen Therapeutics’ investigational new drug (IND) application for ...

Q2 2025 net product revenue for ZORYVE® (roflumilast) was $81.5 million, a 164% increase compared to Q2 of 2024, and a 28% increase compared to Q1 of 2025, driven by strong portfolio demand ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the ...